887586-48-3

Basic information

• Product Name: 2-(4-BROMO-2,3-DIFLUOROPHENYL)ACETIC ACID
• Synonyms: 2-(4-BROMO-2,3-DIFLUOROPHENYL)ACETIC ACID;4-bromo-2,3-difluorophenylacetic acid
• CAS NO: 887586-48-3
• Molecular Formula: C8H5BrF2O2
• Molecular Weight: 251.0249064
• Mol File: 887586-48-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-BROMO-2,3-DIFLUOROPHENYL)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMO-2,3-DIFLUOROPHENYL)ACETIC ACID(887586-48-3)
• EPA Substance Registry System: 2-(4-BROMO-2,3-DIFLUOROPHENYL)ACETIC ACID(887586-48-3)

Safety Data

• Hazardous Substances Data: 887586-48-3(Hazardous Substances Data)

Usage

Description

2-(4-bromo-2,3-difluorophenyl)acetic acid is a chemical compound that belongs to the class of acetic acid derivatives. It is characterized by a molecular structure containing a phenyl group with bromo and difluoro substituents, attached to an acetic acid moiety.

Uses

Used in Pharmaceutical Industry:
2-(4-bromo-2,3-difluorophenyl)acetic acid is used as a building block for the synthesis of more complex organic compounds with specific properties and applications. It has potential biological activities and is the subject of research for potential therapeutic and pharmaceutical applications.
Used in Agrochemical Industry:
2-(4-bromo-2,3-difluorophenyl)acetic acid is used as a building block for the synthesis of agrochemicals with specific properties and applications.
Used in Materials Science:
2-(4-bromo-2,3-difluorophenyl)acetic acid is used as a building block for the synthesis of materials with specific properties and applications.

Upstream product

• 1627857-25-3 2-(4-bromo-2,3-difluorophenyl)acetonitrile 
• 162744-56-1 1-bromo-4-(bromomethyl)-2,3-difluorobenzene 
• 162744-55-0 (4-bromo-2,3-difluorophenyl)methanol 
• 194804-91-6 4-bromo-2,3-difluoro-benzoic acid 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.